This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: September 13, 2005
Last updated: November 15, 2016
Last verified: November 2016
Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth hormone (GH), generally caused by a GH-secreting pituitary adenoma. This study will assess the long-term safety and efficacy of pasireotide in patients with acromegaly.

Condition Intervention Phase
Acromegaly Drug: Pasireotide Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Circulating GH- and IGF-1 concentrations measured every 4 weeks [ Time Frame: Every 6 months ]

Secondary Outcome Measures:
  • Long-term safety and efficacy of multiple doses of Pasireotide s.c. [ Time Frame: Every 3 months ]

Enrollment: 30
Study Start Date: August 2004
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pasireotide s.c. (SOM230) Drug: Pasireotide


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who have completed all four treatment regimens in the core study CSOM230B2201 and achieved biochemical control in GH and IGF-1 levels after at least one month of pasireotide administration at any of the three doses
  • Patients who did not experience any unacceptable adverse events or tolerability issues during the core study CSOM230B2201

Exclusion Criteria:

  • Patients who experienced or developed compression of the optic chiasm causing any visual field defect during the core study CSOM230B2201
  • Patients who required a surgical intervention for relief of any sign or symptom associated with tumor compression during the core study CSOM230B2201 Patients who experienced or developed congestive heart failure, unstable angina, sustained ventricular tachycardia, ventricular fibrillation or acute myocardial infraction during the core study CSOM230B2201

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00171730

United States, California
Cedars Sinai Medical Center Dept. of Pituitary Ctr.
Los Angeles, California, United States, 90048
United States, Michigan
University of Michigan Health System StudyCoordinatorCSOM230B2201E1
Ann Arbor, Michigan, United States, 48109
United States, New York
NYU / VA Medical Center
New York, New York, United States, 10010
Australia, Queensland
Novartis Investigative Site
Woolloongabba, Queensland, Australia, 4102
Novartis Investigative Site
Edegem, Belgium, 2650
Novartis Investigative Site
Toulouse Cédex 4, France, 31043
Novartis Investigative Site
Essen, Germany, 45122
Novartis Investigative Site
Muenchen, Germany, 80336
Novartis Investigative Site
Napoli, Italy, 80131
Novartis Investigative Site
Lausanne, Switzerland, 1011
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Study Chair: Novartis Novartis
  More Information

Additional Information:
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00171730     History of Changes
Other Study ID Numbers: CSOM230B2201E1
2004-002849-12 ( EudraCT Number )
Study First Received: September 13, 2005
Last Updated: November 15, 2016

Keywords provided by Novartis ( Novartis Pharmaceuticals ):

Additional relevant MeSH terms:
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases processed this record on September 21, 2017